Skip to main content
Terug
Watch Compare

AXIM BIOTECHNOLOGIES, INC.

Datakwaliteit: 100%
AXIM
OTC Manufacturing Chemicals
€ 0,01
€ 0,00 (0,00%)
Marktkapitalisatie: 1,93 M
Prijs
€ 0,01
Marktkapitalisatie
1,93 M
Dagbereik
€ 0,01 — € 0,01
52-Weeksbereik
€ 0,00 — € 0,03
Volume
223.916
Openen € 0,01
50D / 200D Gem.
€ 0,01
44,95% below
50D / 200D Gem.
€ 0,01
36,84% below

Quick Summary

Belangrijkste Punten

Revenue declined -52,85% annually over 5 years
Negative free cash flow of -752.995,0
Revenue growth is accelerating — 1Y growth exceeds 5Y average by 398,12%
Capital efficient — spends only 3,40% of revenue on capex

Groei

Revenue Growth (5Y)
-52,85%
Onder sectorgemiddelde (1,82%)
Revenue (1Y)345,27%
Earnings (1Y)N/A
FCF Growth (3Y)N/A

Kwaliteit

Return on Equity
N/A
ROICN/A
Net Margin-4452,06%
Op. Margin-2490,35%

Veiligheid

Debt / Equity
N/A
Current Ratio0,00
Interest Coverage-5,62

Waardering

PE (TTM)
-0,47
Boven sectorgemiddelde (-1,48)
P/B RatioN/A
EV/EBITDAN/A
Dividend YieldN/A

Koershistorie

Financiële Trends

Sectorvergelijking

vs Manufacturing sector mediaan (1364 peers)
Metriek Aandeel Sector Mediaan
P/E -0,5 -1,5
P/B — 1,6
ROE % — -53,4
Net Margin % -4452,1 -41,5
Rev Growth 5Y % -52,9 1,8
D/E — 0,3

All Fundamental Metrics
Growth
Revenue Growth (1Y) 345,27% Revenue Growth (3Y) -19,15%
Earnings Growth (1Y) N/A Earnings Growth (3Y) N/A
Revenue Growth (5Y) -52,85% Earnings Growth (5Y) N/A
Profitability
Revenue (TTM) 92.898,0 Net Income (TTM) -4,14 M
ROE N/A ROA -107,95%
Gross Margin N/A Operating Margin -2490,35%
Net Margin -4452,06% Free Cash Flow (TTM) -752.995,0
ROIC N/A FCF Growth (3Y) N/A
Safety
Debt / Equity N/A Current Ratio 0,00
Interest Coverage -5,62 Asset Turnover 0,02
Working Capital -6,55 M Tangible Book Value -9,53 M
Dividends
Dividend Yield N/A Payout Ratio N/A
Dividend Growth (3Y) N/A Dividend Growth (5Y) N/A
Consecutive Div Years N/A
Valuation
P/E Ratio -0,47 Forward P/E N/A
P/B Ratio N/A P/S Ratio 20,79
PEG Ratio N/A Forward PEG N/A
EV/EBITDA N/A Fwd EV/EBITDA N/A
Forward P/S N/A Fwd Earnings Yield N/A
FCF Yield -38,99%
Market Cap 1,93 M Enterprise Value 7,90 M
Per Share
EPS (Diluted TTM) -0,02 Revenue / Share 0,00
FCF / Share 0,00 OCF / Share 0,00
EPS CAGR (1Y) -200,00% EPS CAGR (5Y) N/A
EPS CAGR (10Y) N/A
Efficiency
CapEx / Revenue 3,40% FCF Conversion 18,21%
SBC-Adj. FCF -914.458 Growth Momentum 398,12

Income Statement

Annual, most recent first
Metric FY2023 FY2022 FY2021 FY2020 FY2019
Revenue 39.518,0 8.875,0 60.460,0 0,0 799.483,0
Net Income -8,06 M -6,24 M -16,03 M -6,41 M -6,45 M
EPS (Diluted) -0,04 0,04 -0,12 -0,06 —
Gross Profit — — — 0,0 223.789,0
Operating Income -2,75 M -4,65 M -13,97 M -4,95 M -6,51 M
EBITDA — — — — —
R&D Expenses 125.496,0 153.697,0 284.869,0 426.708,0 2,45 M
SG&A Expenses 2,24 M 4,08 M — — —
D&A 427.019,0 426.126,0 2,12 M — —
Interest Expense 140.000,0 140.000,0 247.792,0 234.754,0 248.636,0
Income Tax 0,0 0,0 0,0 0,0 0,0

Balance Sheet

Annual, most recent first
Metric FY2023 FY2022 FY2021 FY2020 FY2019
Total Assets 4,12 M 4,21 M 5,32 M 11,31 M 1,69 M
Total Liabilities 11,78 M 9,04 M 7,66 M 9,75 M 8,45 M
Shareholders' Equity -7,66 M -4,83 M -2,34 M 1,57 M -6,76 M
Total Debt — — 180,0 180,0 5.000,0
Cash & Equivalents — 47.282,0 452.963,0 457.181,0 511.630,0
Current Assets 156.457,0 103.979,0 636.613,0 713.104,0 1,64 M
Current Liabilities 5,98 M 3,39 M 2,58 M 1,50 M 3,40 M